Laboratory of Renal Physiology, Department of Physiology, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil.
Rheumatology Division, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil.
Clin Exp Pharmacol Physiol. 2021 Jul;48(7):978-986. doi: 10.1111/1440-1681.13495. Epub 2021 Apr 8.
Testosterone esters are hormones commonly used for affirming gender identity in transmen. The present study evaluates the effect of testosterone on renal morphology and function in an animal model submitted to cross-sex hormone therapy used for transmen. Two-month-old Wistar rats were divided into three groups: male control (MC), female control (FC), and female on testosterone therapy (FTT). The FTT group received testosterone cypionate (3.0 mg/kg, i.m.), and the MC and MF groups received vehicle oil every 10 days for 4 months. Renal function and indirect systolic blood pressure (SBP) measurements were evaluated at 6 months of age. Plasma and urine concentrations of urea, creatinine, sodium, potassium, osmolality, and glomerular filtration rate (GFR) were measured. The kidneys were weighed, paraffin-embedded, and histological sections were prepared to evaluate the glomerular area. We verified that the FTT group, in comparison to FC, had increased kidney weight [MC, 3.2 ± 0.05; FC, 1.8 ± 0.04; FTT, 2.2 ± 0.06; g], decreased urine osmolarity [MC, 486.9 ± 18.3; FC, 1012.0 ± 5.4; FTT, 768.2 ± 40.3 mOsm/L/g kw], reduced GFR [MC, 0.77 ± 0.04; FC, 0.78 ± 0.02; FTT, 0.67 ± 0.03; mL/min/g kw], larger glomerular area [MC, 9334 ± 120.8; FC, 7884 ± 112.8; FTT, 9078 ± 133.4 µm ], and higher SBP [MC, 126 ± 3.4; FC, 119 ± 1.0; FTT, 131 ± 1.4; mmHg]. Sodium excretion was higher in FC and FTT in comparison to MC [MC, 0.34 ± 0.05; FC, 0.56 ± 0.06; FTT, 0.54 ± 0.04; mEq/24 h/g kw]. Cross-sex hormone therapy with testosterone in female rats induces renal morphofunctional changes and may underlie increased systolic pressure, suggesting an adaptation similar to what is observed in transmen on long-term testosterone therapy.
睾酮酯是一种常用于确认跨性别男性性别认同的激素。本研究评估了睾酮对接受跨性别男性使用的跨性别激素治疗的动物模型的肾脏形态和功能的影响。将 2 个月大的 Wistar 大鼠分为三组：雄性对照组（MC）、雌性对照组（FC）和接受睾酮治疗的雌性组（FTT）。FTT 组接受曲安西龙（3.0mg/kg，肌内注射），MC 和 MF 组每 10 天接受一次载体油，共 4 个月。在 6 个月大时评估肾功能和间接收缩压（SBP）。测量血浆和尿液中尿素、肌酐、钠、钾、渗透压和肾小球滤过率（GFR）的浓度。测量肾脏重量，石蜡包埋，制备组织学切片以评估肾小球面积。我们发现与 FC 相比，FTT 组的肾脏重量增加[MC，3.2±0.05；FC，1.8±0.04；FTT，2.2±0.06；g]，尿渗透压降低[MC，486.9±18.3；FC，1012.0±5.4；FTT，768.2±40.3 mOsm/L/g kw]，GFR 降低[MC，0.77±0.04；FC，0.78±0.02；FTT，0.67±0.03；mL/min/g kw]，肾小球面积增大[MC，9334±120.8；FC，7884±112.8；FTT，9078±133.4 µm]，SBP 升高[MC，126±3.4；FC，119±1.0；FTT，131±1.4；mmHg]。与 MC 相比，FC 和 FTT 的钠排泄量增加[MC，0.34±0.05；FC，0.56±0.06；FTT，0.54±0.04；mEq/24 h/g kw]。在雌性大鼠中进行的跨性别激素治疗用睾酮会引起肾脏形态和功能变化，并可能导致收缩压升高，这表明类似于长期接受睾酮治疗的跨性别男性的适应性变化。
